• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

作者信息

Jain R K

机构信息

Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School Boston, Massachusetts, USA.

出版信息

Nat Med. 2001 Sep;7(9):987-9. doi: 10.1038/nm0901-987.

DOI:10.1038/nm0901-987
PMID:11533692
Abstract
摘要

相似文献

1
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.用抗血管生成疗法使肿瘤血管正常化：联合治疗的新范例。
Nat Med. 2001 Sep;7(9):987-9. doi: 10.1038/nm0901-987.
2
Tumour vascularisation: a druggable target.肿瘤血管生成：一个可药物作用的靶点。
Curr Opin Pharmacol. 2009 Apr;9(2):96-101. doi: 10.1016/j.coph.2008.10.004. Epub 2008 Dec 4.
3
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.当前癌症个体化抗血管生成治疗的关注点与挑战。
Expert Rev Anticancer Ther. 2009 Oct;9(10):1413-6. doi: 10.1586/era.09.116.
4
Taking down tumors: vascular disrupting agents entering clinical trials.攻克肿瘤：血管破坏剂进入临床试验阶段。
J Natl Cancer Inst. 2005 Sep 7;97(17):1244-5. doi: 10.1093/jnci/dji298.
5
Antiangiogenic therapy: creating a unique "window" of opportunity.抗血管生成疗法：创造独特的“机会之窗”。
Cancer Cell. 2004 Dec;6(6):529-31. doi: 10.1016/j.ccr.2004.12.003.
6
Targeting the tumor vasculature: a strategy to improve radiation therapy.靶向肿瘤血管：一种改善放射治疗的策略。
Expert Rev Anticancer Ther. 2004 Apr;4(2):321-7. doi: 10.1586/14737140.4.2.321.
7
Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.聚乙二醇化阳离子脂质体靶向血管生成血管的奥沙利铂抑制背气囊小鼠模型中的血管生成。
J Control Release. 2009 Feb 20;134(1):18-25. doi: 10.1016/j.jconrel.2008.10.018. Epub 2008 Nov 5.
8
Therapeutic targeting of the tumor vasculature.肿瘤血管系统的治疗性靶向作用。
Semin Radiat Oncol. 2004 Jul;14(3):222-32. doi: 10.1016/j.semradonc.2004.04.009.
9
Potential of DMXAA combination therapy for solid tumors.
Expert Rev Anticancer Ther. 2002 Oct;2(5):593-603. doi: 10.1586/14737140.2.5.593.
10
Angiogenesis in life, disease and medicine.生命、疾病与医学中的血管生成
Nature. 2005 Dec 15;438(7070):932-6. doi: 10.1038/nature04478.

引用本文的文献

1
Physiologically-based pharmacokinetic model for CAR-T cells delivery and efficacy in solid tumors.基于生理的药代动力学模型用于实体瘤中CAR-T细胞的递送与疗效研究
bioRxiv. 2025 Aug 21:2025.08.20.671229. doi: 10.1101/2025.08.20.671229.
2
The Roles of RNA-Binding Proteins in Vasculogenic Mimicry Regulation in Glioblastoma.RNA结合蛋白在胶质母细胞瘤血管生成拟态调节中的作用
Int J Mol Sci. 2025 Aug 18;26(16):7976. doi: 10.3390/ijms26167976.
3
Natural medicines target tumor vascular microenvironment to inhibit tumor.天然药物靶向肿瘤血管微环境以抑制肿瘤。
Genes Dis. 2025 Apr 8;12(6):101623. doi: 10.1016/j.gendis.2025.101623. eCollection 2025 Nov.
4
Linking tumour angiogenesis and tumour immunity.将肿瘤血管生成与肿瘤免疫联系起来。
Nat Rev Immunol. 2025 Aug 14. doi: 10.1038/s41577-025-01211-z.
5
Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial.呋喹替尼和信迪利单抗联合SOX作为局部可切除的晚期胃/胃食管交界腺癌围手术期治疗：一项前瞻性、单臂、II期临床试验的研究方案
Front Immunol. 2025 Jul 29;16:1638316. doi: 10.3389/fimmu.2025.1638316. eCollection 2025.
6
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study.阿替利珠单抗和贝伐单抗联合或不联合放疗与多西他赛治疗既往接受过检查点抑制剂和化疗的转移性非小细胞肺癌患者：随机1b/II期MORPHEUS-Lung研究结果
J Immunother Cancer. 2025 Aug 4;13(8):e011892. doi: 10.1136/jitc-2025-011892.
7
Detecting vascular normalization in epithelial ovarian cancer.检测上皮性卵巢癌中的血管正常化。
Med Oncol. 2025 Aug 3;42(9):401. doi: 10.1007/s12032-025-02929-5.
8
Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3.区分世界卫生组织2级和3级异柠檬酸脱氢酶（IDH）突变型星形细胞瘤的临床和神经病理学标准。
J Neurooncol. 2025 Jul 23. doi: 10.1007/s11060-025-05173-z.
9
Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.不可切除胆管癌的靶向治疗和免疫治疗
Chin Med J (Engl). 2025 Aug 20;138(16):1904-1926. doi: 10.1097/CM9.0000000000003705. Epub 2025 Jul 21.
10
Tumor microenvironments with an active type I IFN response are sensitive to inhibitors of heme degradation.具有活跃I型干扰素反应的肿瘤微环境对血红素降解抑制剂敏感。
JCI Insight. 2025 Jul 8;10(16). doi: 10.1172/jci.insight.191017. eCollection 2025 Aug 22.